Vital Farms (VITL) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.43 per share a year ago.

AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago.

Shares of Alphabet NASDAQ: GOOGL, Google's parent company, have struggled in 2025, falling over 20% year-to-date and officially entering bear market territory. The tech giant has come under pressure amid shifting investor sentiment and intensifying competition.

Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Pet Cancer Awareness Month, a time devoted to raising awareness about cancer in pets, particularly in dogs and cats. "According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, …

Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D.

Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.

Expects to Achieve Projected Annual Revenue of $90 Million BEIJING , May 8, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), a Nevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced its revenue for the third quarter of fiscal year 2025, ended March 31, 2025, which is expected to be approximately $51.9 million, representing an increase of approximately 164.6%, as compared to approximately $19.6 million for the same period in the previous year. The expected increase was primarily driven by sustained growth in the Company's 5G+AI multimodal digital business, continuing the …

Phillips 66 shares have underperformed, losing about 25% over the past year, due to weak refining margins and macroeconomic challenges. Q1 results were weak, with a $0.90 loss per share, but turnaround work should improve margins and throughput in the near term. The company is reducing debt and focusing on shareholder returns, with potential upside from asset sales and improved refining margins.

NEW YORK--(BUSINESS WIRE)--Optimum, a leading provider of fiber internet, mobile, TV and phone services, today announces the evolution of its value-add experience suite with the launch of a brand-new bundled streaming offer for customers. Beginning next week, eligible video and internet customers will be provided with a promotional offer of six complimentary months of Disney+, Hulu Bundle Basic, a new add-on to the Optimum connectivity experience, all on Optimum. The new bundled streaming offer.

Restaurant Brands is the latest fast-food giant to cite weak first quarter demand.

Alphabet (GOOGL) shares fell sharply on Wednesday after testimony from an Apple (AAPL) executive reveal the iPhone maker's desire to adopt A.I. search engines for its devices, potentially replacing Google Search as a go-to option.

BlackSky Technology Inc. (BKSY) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.88 per share a year ago.

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year ago.

Altice USA, Inc. (ATUS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.05 per share a year ago.

The correction is to the headline only TAMPA, FL / ACCESS Newswire / May 8, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further …

Experienced partner to launch rollout of up to hundreds of GPS monitoring units from SuperCom's PureSecurity Suite TEL AVIV, Israel , May 8, 2025 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and cybersecurity sectors, today announced that it has signed a new contract with a seasoned electronic monitoring service provider based in Canada. This agreement marks another milestone in SuperCom's North American expansion and reinforces its growing global presence in the electronic monitoring (EM) market.

-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP.

SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical and certain of West Pharmaceutical's current and former top executives with violations …

BeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra. Brukinsa, a BTK inhibitor, has shown impressive revenue growth and market share gains, with significant potential for future expansion and revenue generation. Tevimbra, while facing intense competition, shows promise with recent FDA approvals and ongoing trials targeting various cancers.

Pershing Square's $900 million investment in Howard Hughes aims to transform it into a modern-day Berkshire Hathaway, with a 48% premium to the stock price. Howard Hughes' management believes the Net Asset Value is between $100 and $115, aligning with Pershing Square's increased bid to $100 per share. The deal includes a 1.5% management fee and quarterly fees, with Pershing Square limiting its voting power to 40% and beneficial ownership to 47%.